^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Mantle Cell Lymphoma
    Drug:Imbruvica (ibrutinib) (BTK inhibitor) +
    Rituxan (rituximab) (CD20 inhibitor) +
    lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The panel has included this regimen with a category 2B recommendation...relapsed or refractory MCL in which the combination of ibrutinib, lenalidomide, and rituximab resulted in an ORR of 76%...